Cell/Gene Tx channel feed

Au­to­lus tips its hand, bags $220M as CAR-T show­down with Gilead looms

3 years ago
Financing
R&D

Avro­bio touts ear­ly clin­i­cal da­ta and plans new gene ther­a­py tri­al in 2023

3 years ago
R&D

Nkar­ta un­der­scores safe­ty of CAR-NK, boasts ear­ly re­spons­es

3 years ago
R&D

Gene ther­a­py goes acoustic as ARCH-backed biotech launch­es with ul­tra­sound gene de­liv­ery plat­form

3 years ago
Financing

Ver­tex-part­nered gene ther­a­py biotech Affinia scraps IPO plans

3 years ago
Financing
Startups

Beam's base-edit­ed al­lo­gene­ic CAR-T gets FDA go-ahead af­ter four-month wait

3 years ago
FDA+

Twist Bio­science’s 'fac­to­ry of the fu­ture' in Ore­gon could de­liv­er with com­pet­i­tive pric­ing, SVB Se­cu­ri­ties says

3 years ago
Pharma
Manufacturing

Bris­tol My­ers scraps gene ther­a­py deal with uniQure for car­dio­vas­cu­lar dis­eases

3 years ago
Deals

Up­dat­ed: As­traZeneca jumps deep­er in­to cell ther­a­py 2.0 space with $320M biotech M&A

3 years ago
Deals

MIT re­searchers re­veal DNA 'Paste' tech be­hind lat­est gene edit­ing start­up

3 years ago
Discovery

One hur­dle down? FDA won't hold ad­comm for Bio­Mar­in's he­mo­phil­ia gene ther­a­py af­ter all

3 years ago

CSL lands FDA ap­proval for he­mo­phil­ia B gene ther­a­py, sets $3.5M list price

3 years ago
FDA+

Mak­er of new gene ther­a­py vec­tor launch­es its sec­ond com­pa­ny, look­ing to ze­ro in on rare skin con­di­tions

3 years ago
Startups

Gene ther­a­py flunks PhII/III study, but for­mer Sarep­ta part­ner sees a path for­ward — if it can find the cash

3 years ago
R&D

Leg­end CEO spells out path to $5B in sales for mul­ti­ple myelo­ma CAR-T ther­a­py Carvyk­ti

3 years ago
China

FDA hits Io­vance with one more de­lay for TIL ther­a­py, ex­tend­ing BLA fil­ing un­til 2023

3 years ago
FDA+

Ed­i­tas halts lead CRISPR pro­gram af­ter ef­fi­ca­cy da­ta un­der­whelm

3 years ago
R&D

GSK's cell ther­a­py re­treat hits an­oth­er part­ner as drug­mak­er ex­its Im­mat­ics col­lab­o­ra­tion

3 years ago
Deals

With new up­date in hand, In­tel­lia CEO now claims one-time HAE gene edit­ing treat­ment 'may be a func­tion­al cure'

3 years ago
R&D

Supreme Court toss­es Bris­tol My­er­s' bid to re­vive $1.2B CAR-T case against Gilead

3 years ago
Law

An­oth­er road­block looms for Bio­Mar­in's he­mo­phil­ia A gene ther­a­py — but it might not take too long

3 years ago
FDA+

ONO ex­er­cis­es Fate CAR-T op­tion in lat­est twist to part­ner­s' four-year deal

3 years ago
Pharma

With all hands on deck for lead sick­le cell tri­al, Beam pulls back clin­i­cal plans for sec­ond base edit­ing ther­a­py

3 years ago
R&D

Up­dat­ed: Verve's land­mark base edit­ing tri­al for car­dio drug runs in­to FDA hold

3 years ago
R&D
FDA+
First page Previous page 23242526272829 Next page Last page
A service from the Financial Times